University of Birmingham creates a spinout specifically for the purpose of developing its gene modifying T cell research that targets solid tumours.
Alta Innovations, the commercial arm of the University of Birmingham, has created an immuno-oncology spinout called Chimeric Therapeutics.
Chimeric will hold all intellectual property rights relating to discoveries based around using gene modifying T cells to target and treat solid tumours.
It has been created in conjunction with UK-based cancer charity Cancer Research UK and Cell Therapy Catapult, a centre of excellence in innovation in cell and gene therapy backed by Innovate UK, a UK non-departmental public body.
The research…
